ABT vs JNJ
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | ABT | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $116.64 | $270.24 | |
| Market cap as of 2026-08-24 | $203.2B | $651.3B | |
| P/E as of 2026-08-24 | 35.52 | 29.93 | JNJ lower |
| PEG as of 2026-08-24 | 3.63 | 3.39 | JNJ lower |
| Net margin as of 2026-08-24 | +11.7% | +21.5% | JNJ higher |
| Gross margin as of 2026-08-24 | +56.8% | +68.0% | JNJ higher |
| Operating margin as of 2026-08-24 | +15.8% | +25.7% | JNJ higher |
| ROE as of 2026-08-24 | +10.5% | +25.7% | JNJ higher |
| ROA as of 2026-08-24 | +5.6% | +10.6% | JNJ higher |
| Debt / equity as of 2026-08-24 | 0.64 | 0.58 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-24 | +8.1% | +8.1% | Tie |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +6.2% | JNJ higher |
| Dividend yield as of 2026-08-24 | +2.0% | +3.1% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | 4 | 5 | JNJ higher |
| Beta as of 2026-08-24 | 0.58 | 0.20 | |
| 1-year return as of 2026-08-21 close | -11.6% | +51.0% | JNJ higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.